For Q1 FY2026 ended March 31, 2026, Tactile Systems Technology reported revenue of $75.3 million, up 22.8% year-over-year. Net loss was $1.8 million, improving 40.7% from a net loss of $3.0 million in the prior year. Operating loss was $1.5 million, a 66.2% improvement. Diluted EPS was -$0.08, compared to -$0.13 a year ago. The company had $75.0 million in cash, $217.9 million in equity, and no long-term debt.
•Revenue grew 22.8% YoY to $75.3 million.
•Net loss narrowed 40.7% to $1.8 million.
•Operating loss improved 66.2% to $1.5 million.
•No long-term debt; cash of $75.0 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Tactile Systems Technology, Inc., a medical technology company develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and types of edema and leg ulcers Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds
Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema. Its portfolio also includes Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment to share their progress with their doctor, and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Incorporated in 1995, Tactile Systems Technology is headquartered in Minneapolis, Minnesota.
Tactile Systems Technology, Inc. is a medical technology company that develops and provides medical devices to treat underserved chronic diseases in the United States. Its primary product is the Flexitouch Plus system, a pneumatic compression device used for treating lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and various types of edema and leg ulcers. The company also offers the Entre Plus System for at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds, as well as the Nimbl pneumatic compression platform for upper extremity lymphedema. Additionally, Tactile Systems provides the AffloVest, a portable high frequency chest wall oscillation vest for patients with retained pulmonary secretions from bronchiectasis, cystic fibrosis, and neuromuscular disorders. The company also offers a mobile application called Kylee to help patients learn about lymphedema, track symptoms, and share progress with their doctors.
On which stock exchange is Tactile Systems Technology (TCMD) listed and in what currency?
Tactile Systems Technology, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol TCMD. The company's financials and stock trading are denominated in US Dollars (USD). As a US-based company, its shares are traded in the United States, and investors typically use US dollars to buy and sell TCMD stock.
What sector and industry does Tactile Systems Technology (TCMD) belong to?
Tactile Systems Technology operates in the Healthcare sector, specifically within the Medical Devices industry. This means the company is involved in designing, manufacturing, and marketing medical equipment and devices used for diagnosis, monitoring, or treatment of medical conditions. In Tactile Systems' case, its focus is on pneumatic compression devices and other therapies for chronic conditions such as lymphedema, venous insufficiencies, and respiratory disorders. The Medical Devices industry is highly regulated and requires significant research and development, as well as compliance with standards set by bodies like the FDA.
Where is Tactile Systems Technology (TCMD) headquartered and what markets does it serve?
Tactile Systems Technology, Inc. is headquartered in Minneapolis, Minnesota, United States. The company primarily serves the US market, as indicated by its description summary which states it develops and provides medical devices in the United States. While its products are designed to treat chronic diseases like lymphedema, venous insufficiencies, and bronchiectasis, the company's operations and sales appear to be concentrated domestically. The headquarters location in Minneapolis places it in a region known for a strong medical technology cluster, which may provide access to talent and resources.
What are the main products in Tactile Systems Technology's (TCMD) portfolio?
Tactile Systems Technology's product portfolio includes several key medical devices. The Flexitouch Plus system is a pneumatic compression device for treating lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and various edemas and leg ulcers. The Entre Plus System is designed for at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The Nimbl is a pneumatic compression platform specifically for upper extremity lymphedema. Additionally, the AffloVest is a portable high frequency chest wall oscillation vest for patients with retained pulmonary secretions from bronchiectasis, cystic fibrosis, and neuromuscular disorders. The company also offers the Kylee mobile application, which helps patients learn about lymphedema, track symptoms and treatment, and share progress with their doctors.